SKYTROFA

Peak

lonapegsomatropin-tcgd

BLAINJECTIONINJECTABLE
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1

Mechanism of Action

Pharmacologic Class:

Recombinant Human Growth Hormone

Clinical Trials (1)

NCT05820672N/ARecruiting

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Started Mar 2023
900 enrolled
Growth Hormone Deficiency